211 related articles for article (PubMed ID: 17448017)
1. Expression of oestrogen receptor-beta in apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Kasumi F; Sawabe M; Arai T; Hosoi T; Yoshimura N; Harada N; Younes M; Sakamoto G
Histopathology; 2007 Mar; 50(4):425-33. PubMed ID: 17448017
[TBL] [Abstract][Full Text] [Related]
2. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
3. Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast.
Honma N; Saji S; Kurabayashi R; Aida J; Arai T; Horii R; Akiyama F; Iwase T; Harada N; Younes M; Toi M; Takubo K; Sakamoto G
APMIS; 2008 Oct; 116(10):923-30. PubMed ID: 19132986
[TBL] [Abstract][Full Text] [Related]
4. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
5. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
6. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
[TBL] [Abstract][Full Text] [Related]
8. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.
Kaya H; Bozkurt SU; Erbarut I; Djamgoz MB
Pathol Res Pract; 2008; 204(6):367-71. PubMed ID: 18342452
[TBL] [Abstract][Full Text] [Related]
9. 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.
Oduwole OO; Li Y; Isomaa VV; Mäntyniemi A; Pulkka AE; Soini Y; Vihko PT
Cancer Res; 2004 Oct; 64(20):7604-9. PubMed ID: 15492288
[TBL] [Abstract][Full Text] [Related]
10. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression.
Kolár Z; Murray PG; Zapletalová J
Neoplasma; 2002; 49(2):110-3. PubMed ID: 12088102
[TBL] [Abstract][Full Text] [Related]
11. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H
Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513
[TBL] [Abstract][Full Text] [Related]
13. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.
Barnes NL; Boland GP; Davenport A; Knox WF; Bundred NJ
Br J Surg; 2005 Apr; 92(4):429-34. PubMed ID: 15736216
[TBL] [Abstract][Full Text] [Related]
14. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
15. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
16. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
18. Expression of 5α-reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness.
Kasashima S; Kawashima A; Ozaki S; Nakanuma Y
Histopathology; 2012 May; 60(6B):E51-7. PubMed ID: 22486281
[TBL] [Abstract][Full Text] [Related]
19. [Expression and significance of estrogen receptor isoforms in the development of human breast carcinoma].
Wang S; Wang S; Zhang JQ; Qiao XM; Yang DQ; Tong FZ; Ye YJ; Cui ZR
Zhonghua Wai Ke Za Zhi; 2004 Jul; 42(13):792-4. PubMed ID: 15363297
[TBL] [Abstract][Full Text] [Related]
20. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
